Authors

Latest:

Dr Lin on Findings From the CARTITUDE-1 Trial in Relapsed/Refractory Multiple Myeloma

Yi Lin, MD, PhD, discusses findings from the primary analysis of the phase 1/2 CARTITUDE-1 trial of the BCMA-targeting CAR T-cell therapy ciltacabtagene autoleucel in patients with relapsed/refractory multiple myeloma.

Mount Sinai

Latest:

Study Identifies How Ovarian Cancer Protects Itself, Paves Way for Improved Immunotherapy Approach

Eczema-linked protein helps cancer survive, suggesting potential for skin drug-based treatment.

Yazan Madanat, MD

UT Southwestern Medical Center

Latest:

Final Thoughts on Recent Data Updates in MDS

Closing their discussion, the panel shares some parting comments on the recent updates in the MDS treatment landscape and hopes for the future.

Jason Henry, MD

Latest:

Recent Updates in Early Onset Colorectal Cancer: What We Know and Where to Go

Oncologists globally explore trends, challenges in diagnosis, and future directions in patients with colorectal cancer.

Jose Maria Mazarico Gallego, MD

Latest:

Dr. Gallego on the Impact of COVID-19 on Cancer Care in Spain

Jose Maria Mazarico Gallego, MD, discusses the impact of the COVID-19 pandemic on cancer care in Spain.

Neil Vasan, MD, PhD

Latest:

Dr. Vasan on Advancing the Treatment of Small HER2+ Breast Cancer

Neil Vasan, MD, discusses advances made in the treatment of patients with small HER2-positive breast cancer.

Michelina Cairo, MD

Latest:

Dr Cairo on the Safety Profiles of T-DM1 vs T-DXd in HER2+ Metastatic Breast Cancer

Michelina Cairo, MD, discusses the adverse effect profiles of trastuzumab emtansine and trastuzumab deruxtecan in patients with HER2-positive metastatic breast cancer.

Sabina Signoretti, MD

Latest:

Dr Signoretti on the Development of Novel Biomarkers in RCC Using Tissue-Based Analyses

Sabina Signoretti, MD, discusses research into the development of novel spatial biomarkers in renal cell carcinoma utilizing tissue-based in situ analyses.

Ignace B. Vergote, MD, PhD

Latest:

Dr Vergote on the Efficacy of Tisotumab Vedotin in Recurrent/Metastatic Cervical Cancer

Ignace B. Vergote, MD, PhD, discusses the efficacy of tisotumab vedotin-tftv in patients with recurrent or metastatic cervical cancer, according to data from the phase 3 innovaTV 301/ENGOT-cx12/GOG-3057 trial (NCT04697628).

Rondell P. Graham, MBBS

Chunxia Su, MD, PhD

Latest:

Camidge and Su Compare Lung Cancer Treatment Strategies in China and the United States

Drs Camidge and Su discuss the aspects of medicine that strengthened Dr Su’s interest in oncology and the details of delivering lung cancer care in China.

Ari Rosenberg, MD

Latest:

Rosenberg Reviews the Evolving Role of Toripalimab in Nasopharyngeal Carcinoma

Dr Rosenberg discusses strategies for managing nasopharyngeal cancer and the role of toripalimab in this treatment paradigm.

Erin Roesch, MD

Latest:

A Dynamic Treatment Landscape Emerges for Early-Stage TNBC

Standard chemotherapy has historically been the mainstay of treatment for patients with diagnoses of early-stage TNBC, but there remains an unmet need to identify novel therapies that improve outcomes and, equally important, to discern which patients may benefit from a given treatment.

John Nakayama, MD

Latest:

Serializer Test 2

Testing individual components

Alison Schram, MD

Latest:

FDA Approval Insights: Zenocutuzumab for NRG1+ Pancreatic Adenocarcinoma and NSCLC: With Alison Schram, MD

Dr Schram discusses the significance of the FDA approval of zenocutuzumab for NRG1 fusion–positive NSCLC and pancreatic adenocarcinoma.

Patrick Boland, MD

Latest:

Dr Boland on the Emergence of KRAS G12C Inhibitors in mCRC

Patrick Boland, MD, discusses the development of therapeutic strategies targeting KRAS G12C mutations in colorectal cancer.

Janeesh Sekkath Veedu, MBBS

Latest:

Dr Sekkath Veedu on Survival Outcomes With Surgery vs Chemoradiation in Stage IIIA NSCLC

Janeesh Sekkath Veedu, MBBS, discusses the survival advantage conferred by surgical-based treatment compared with definitive chemoradiation in patients with stage IIIA non–small cell lung cancer.

Upal Basu Roy, PhD, MPH

Latest:

Dr. Basu Roy on the Challenges of Interpreting Molecular Testing Results in Lung Cancer

Upal Basu Roy, PhD, MPH, discusses the challenges of interpreting molecular testing results in lung cancer.

Thomas Cluzeau, MD, PhD

Latest:

MDS/MPN-RS-T Overlap Syndromes

A brief discussion centered on MDS/MPN-RS-T overlap syndromes, considerations for diagnosis, available treatment options, and updates in the space.

Anne P. O’Dea, MD

Latest:

T-DXd in HER2-Low Disease: DESTINY-Breast06 Data and Patient Selection Insights

Panelists discuss how DESTINY-Breast06 demonstrated meaningful clinical activity of trastuzumab deruxtecan in both HER2-low and ultralow metastatic breast cancer populations.